| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9492384 | ALMIRALL | Microemulsion and sub-micron emulsion process and compositions |
Aug, 2025
(1 year, 11 months from now) | |
| US8962000 | ALMIRALL | Microemulsion and sub-micron emulsion process and compositions |
Aug, 2025
(1 year, 11 months from now) | |
| US8460641 | ALMIRALL | Microemulsion process and composition |
Aug, 2027
(3 years from now) | |
Verdeso is owned by Almirall.
Verdeso contains Desonide.
Verdeso has a total of 3 drug patents out of which 0 drug patents have expired.
Verdeso was authorised for market use on 19 September, 2006.
Verdeso is available in aerosol, foam;topical dosage forms.
Verdeso can be used as treatment of atopic dermatitis.
The generics of Verdeso are possible to be released after 13 August, 2027.
Drugs and Companies using DESONIDE ingredient
Market Authorisation Date: 19 September, 2006
Treatment: Treatment of atopic dermatitis
Dosage: AEROSOL, FOAM;TOPICAL
VERDESO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic